Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease

Jeffrey H. Kordower, Stephane Palfi, Er Yun Chen, Shuang Y. Ma, Timothy Sendera, Elizabeth J. Cochran, Elliott J. Mufson, Richard Penn, Christopher G. Goetz, Cynthia D. Comella

Research output: Contribution to journalArticlepeer-review

353 Scopus citations

Abstract

As part of a safety and tolerability study, a 65-year-old man with Parkinson's disease (PD) received monthly intracerebroventricular injections of glial-derived neurotrophic factor (GDNF). His parkinsonism continued to worsen following intracerebroventricular GDNF treatment. Side effects included nausea, loss of appetite, tingling, L'hermitte's sign, intermittent hallucinations, depression, and inappropriate sexual conduct. There was no evidence of significant regeneration of nigrostriatal neurons or intraparenchymal diffusion of the intracerebroventricular GDNF to relevant brain regions. Alternative GDNF delivery systems should be explored.

Original languageEnglish (US)
Pages (from-to)419-424
Number of pages6
JournalAnnals of Neurology
Volume46
Issue number3
DOIs
StatePublished - 1999
Externally publishedYes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease'. Together they form a unique fingerprint.

Cite this